10x Genomics, Inc. announced the results of its 2026 annual meeting of stockholders held on June 4, 2026, where all proposals submitted to a vote were approved. This includes the election of three directors, the ratification of the company's independent auditor, and the advisory approval of executive compensation.
Key Details
- Director Election: Shareholders elected Serge Saxonov, Benjamin J. Hindson, and John R. Stuelpnagel as Class I directors for three-year terms expiring at the 2029 annual meeting.
- Auditor Ratification: The appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers.